Loading
RRM2 (Ribonucleoside-diphosphate reductase subunit M2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Breast cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Provides the precursors necessary for DNA synthesis. Catalyses the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signalling. Location: Cytoplasm; Nucleus (UniProt). Locus 2p25.1 (HGNC).
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"RRM2" OR ABSTRACT:"RRM2" OR TITLE:"ribonucleotide reductase regulatory subunit M2" OR ABSTRACT:"ribonucleotide reductase regulatory subunit M2" OR TITLE:"Ribonucleoside-diphosphate reductase subunit M2" OR ABSTRACT:"Ribonucleoside-diphosphate reductase subunit M2" OR TITLE:"FLJ25102" OR ABSTRACT:"FLJ25102" OR TITLE:"C2orf48" OR ABSTRACT:"C2orf48") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RRM2, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/rrm2.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/rrm2.json. Licence CC BY-NC 4.0.